Comparative efficacy and safety of first-line treatments in patients with metastatic renal cell cancer: a network meta-analysis based on phase 3 RCTs.

PubWeight™: 0.75^‹?›

🔗 View Article (PMID 26908455)

Published in Oncotarget on March 29, 2016

Authors

Xiaofeng Chang¹^,2^,3, Fan Zhang¹, Tieshi Liu¹, Rong Yang¹, Changwei Ji¹, Xiaozhi Zhao¹, Linfeng Xu¹, Guangxiang Liu¹, Hongqian Guo¹^,4

Author Affiliations

1: Department of Urology, The Affiliated Nanjing Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.
2: Jiangsu Key Laboratory of Molecular and Functional Imaging, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.
3: Collaborative Innovation Center of Suzhou Nano-Science and Technology, Suzhou Key Laboratory of Biomaterials and Technologies, Suzhou, China.
4: Medical School, Southeast University, Nanjing, China.

Associated clinical trials:

SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma | NCT00083889

Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer | NCT00073307

Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma (COMPARZ) | NCT00720941

Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma (ARCC) | NCT00065468

Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma | NCT00334282

Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer | NCT00920816

Articles cited by this ↗

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA (1995) 45.41

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39

Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med (2007) 24.19

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet (2007) 15.92

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 13.52

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol (2010) 13.03

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med (2009) 12.16

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (2011) 12.13

Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol (2007) 11.04

Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med (2013) 10.74

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol (2009) 6.86

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol (2010) 5.08

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol (2010) 4.43

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet (2008) 4.11

Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev (2005) 3.88

Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol (2013) 3.48

Imputing missing standard deviations in meta-analyses can provide accurate results. J Clin Epidemiol (2006) 3.30

Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol (2013) 3.20

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol (2013) 2.63

Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol (2014) 2.53

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2014) 1.93

Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet (2010) 1.81

Novel immunotherapeutic strategies in development for renal cell carcinoma. Eur Urol (2012) 1.60

Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med (2014) 1.43

Metastatic renal cell cancer treatments: an indirect comparison meta-analysis. BMC Cancer (2009) 1.37

Targeted drugs for metastatic renal cell carcinoma. Lancet (2007) 1.36

Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. Br J Cancer (2013) 1.24

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. Br J Cancer (2015) 1.05

Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma. Eur Urol (2015) 0.92

Indirect comparisons of efficacy and safety between seven newer targeted agents for metastatic renal cell carcinoma: A network meta-analysis of randomised clinical trials. Mol Clin Oncol (2014) 0.80